Survival after the onset of chronic lung rejection varies widely, but the overall median sits somewhere around two and a half to four years, depending on the form the rejection takes and how early it is caught. One study of lung transplant recipients found a median survival of roughly 31 months after diagnosis, though individual trajectories ranged from months to well over a decade. The picture is complicated by the fact that chronic lung rejection is not a single disease but rather an umbrella term covering at least two distinct patterns of decline, each with a very different prognosis.
What Chronic Lung Rejection Means in Practice
After a lung transplant, the immune system gradually recognizes the donated organ as foreign. Immunosuppressive medications keep this response in check for most recipients, but over time the transplanted lungs often develop progressive, irreversible damage known as chronic lung allograft dysfunction, or CLAD. This is what clinicians mean by “chronic lung rejection,” and it remains the leading cause of death beyond the first year after transplant. Current global data indicate that the median survival after lung transplantation overall is about six years, or roughly eight years among those who survive the first twelve months. CLAD is the main reason that number is not higher.
Two Phenotypes, Two Very Different Timelines
One of the most important findings in the last two decades is that chronic lung rejection comes in two distinct forms, and the type you develop dramatically changes how long you can expect to live.
The more common form is bronchiolitis obliterans syndrome, or BOS. In BOS, chronic inflammation gradually scars and narrows the small airways while the surrounding lung tissue stays relatively intact. Breathing becomes progressively more obstructed, similar in some ways to COPD. Median survival after a BOS diagnosis is roughly three to five years, with some patients living considerably longer, especially if the disease stabilizes at an early stage.
The less common but far more aggressive form is restrictive allograft syndrome, or RAS. Rather than just targeting the small airways, RAS involves scarring across multiple tissue layers in the lung, restricting the organ’s ability to expand. One landmark study found that RAS patients survived a median of roughly 541 days after onset, compared to about 1,421 days for BOS patients, and that the RAS phenotype was the single strongest predictor of death after CLAD diagnosis. Other analyses put the range for RAS at roughly six to eighteen months. About a third of all CLAD cases turn out to be RAS, which is a sobering proportion given how much worse its outcomes are.
Importantly, lung function decline alone cannot reliably distinguish between the two. Both forms show a drop in airflow, but only RAS shows a shrinking total lung capacity. That distinction requires specific pulmonary function tests and imaging to pick up, which is why monitoring after transplant is so intensive.
What Happens When CLAD Reaches an Advanced Stage
For patients whose disease progresses to severe CLAD despite treatment, the outlook is grim. A recent study following patients with advanced CLAD found a two-year survival rate of just 25% over a median follow-up period. Among the 26 recipients who died in an earlier study, nearly all died in the intensive care unit, and life support was ultimately withdrawn in about 69% of cases. These numbers reflect a reality that families and patients often are not prepared for: once chronic rejection advances past a certain point, the decline can accelerate sharply, and the end-of-life trajectory often involves hospitalization and difficult decisions about continuing aggressive treatment.
What Pushes Chronic Rejection to Develop
Chronic lung rejection rarely appears out of nowhere. Several well-documented triggers make it more likely, and understanding them helps explain why some people develop CLAD early while others go years without it.
- Acute rejection episodes: Even mild episodes of acute cellular rejection after transplant are associated with a higher risk of developing BOS. One study found that even the lowest grade of acute rejection roughly doubled the likelihood of progressing to BOS, while more severe episodes tripled or quadrupled the risk for advanced disease stages.
- Donor-specific antibodies: When the recipient’s immune system produces antibodies that specifically target the donor lung’s tissue markers, the risk of CLAD rises substantially. Persistent antibodies are the key concern. In one cohort, CLAD-free survival at five years was about 56% for patients with persistent donor-specific antibodies versus 77% for those whose antibodies were only transient. Antibodies that also activate the complement system are especially dangerous, with 100% of complement-binding antibodies proving persistent in one analysis.
- Gastroesophageal reflux: Stomach acid chronically reaching the airways appears to be a genuine risk factor, with one meta-analysis finding that reflux disease nearly tripled the hazard of developing BOS.
- Respiratory infections: Viral infections of the lower respiratory tract are repeatedly linked to BOS in the research, serving as inflammatory triggers that may tip the immune balance toward chronic rejection.
The upshot is that aggressive management of these risk factors, including prompt treatment of acute rejection, antibody monitoring, and reflux control, may delay the onset of CLAD. But none of these strategies is a guarantee.
Detecting Chronic Rejection Early
The standard way to diagnose CLAD is through spirometry, the breathing test that measures how much air you can force out and how quickly. A sustained decline in lung function below a certain threshold from your post-transplant best triggers the diagnosis. But spirometry has a significant limitation: by the time the numbers drop enough to meet the formal definition, the disease may already be well established.
CT imaging plays an increasingly important role, particularly in distinguishing BOS from RAS and in catching early abnormalities before lung function testing catches up. CT can detect air trapping in BOS and fibrotic changes in RAS, and it helps rule out other treatable causes of declining function like infection or fluid buildup.
A newer and particularly promising tool is the measurement of donor-derived cell-free DNA (dd-cfDNA) in the recipient’s blood. When transplanted lung cells are damaged, they release fragments of DNA into the bloodstream, and the donor’s DNA can be distinguished from the recipient’s. One study found that dd-cfDNA levels were elevated in patients experiencing both acute rejection and CLAD compared to stable patients, with a detection threshold that achieved sensitivity around 89-95% for different types of rejection. The test is not perfect, and the optimal cutoff values differ across studies, but it represents a move toward catching rejection through a simple blood draw rather than waiting for lung function to deteriorate.
Treatment Options and How Well They Work
There is no cure for established chronic lung rejection. The treatments available are aimed at slowing the decline, stabilizing lung function, or buying time until retransplantation becomes possible. The honest reality is that none of these treatments work reliably for everyone, and the evidence base is thinner than most patients would hope.
The best-supported medical treatment for CLAD is azithromycin, an antibiotic that also has anti-inflammatory properties. A randomized trial found that patients receiving prophylactic azithromycin had better lung function and lower airway inflammation over two years compared to placebo, and that among patients who already had BOS, about half showed improvement with open-label azithromycin treatment. Another study following patients on azithromycin for twelve months found that about a fifth were true responders with improved function, more than half stabilized, and roughly a quarter continued to decline. Patients caught at the earliest stages of BOS were far more likely to respond than those with established disease.
A fascinating recent finding adds nuance to the azithromycin story. Researchers examining the lung microbiome found that azithromycin significantly improved survival only in patients who had a high bacterial burden in their lungs. For patients with low or moderate bacterial loads, the drug had essentially no impact on survival after CLAD diagnosis. This suggests that azithromycin’s benefit may come primarily from its antimicrobial effects rather than its anti-inflammatory properties, and that microbiome profiling could eventually help clinicians decide who should receive it.
Extracorporeal photopheresis, or ECP, is another option used at some centers. This treatment involves drawing blood, exposing white blood cells to a light-sensitizing agent and ultraviolet light, and reinfusing them. A European multi-center analysis found that about 42% of CLAD patients achieved long-term stabilization with ECP, and another 9% actually improved. Five-year survival was 70% in responders and 56% in those who stabilized, compared with only 35% in non-responders. The catch is that almost a quarter of patients died within the first year of starting ECP, and there is no reliable way to predict who will respond.
Antifibrotic Drugs for the Restrictive Form
Because RAS involves extensive fibrosis similar to what occurs in idiopathic pulmonary fibrosis, researchers have turned to antifibrotic medications originally developed for that disease. Pirfenidone and nintedanib have both been tried off-label in small numbers of RAS patients. One case series of eleven RAS patients treated with pirfenidone found that it appeared to slow the decline in lung function, with three patients stabilized long enough to be bridged to a second transplant and three others showing long-term stabilization for up to nearly four years. These results are encouraging but come from very small, uncontrolled studies. Larger randomized trials are still pending, and right now antifibrotics remain experimental for this use.
Retransplantation as a Last Resort
For patients with advanced CLAD who are otherwise good candidates, a second lung transplant is the only option that offers a genuine chance at long-term survival. In selected patients, outcomes after retransplantation can approach those of a first transplant. However, the bar for candidacy is high. Several factors are associated with worse outcomes after a redo: having the second transplant within the first year of the original, older age, poor functional status, and requiring ICU-level care before the procedure. The practical reality is that donor organs remain scarce, and many transplant centers are cautious about listing patients for retransplantation when the supply of lungs already cannot meet the demand for first-time recipients.
How Chronic Rejection Affects Daily Life
The survival numbers tell only part of the story. For many patients, the quality of those years matters as much as the quantity. After CLAD onset, patients experience declines in physical function, energy, and mobility. Breathlessness returns, daily activities become harder, and anxiety and depression become common. Both patients and their caregivers describe CLAD as a return to the pre-transplant state they thought they had escaped, which carries a profound emotional weight.
Pulmonary rehabilitation and physical therapy remain important even after chronic rejection is diagnosed. One case report documented significant gains in walking distance, respiratory muscle strength, and body weight with a structured physical therapy program after transplant. While that particular report focused on post-surgical recovery rather than CLAD specifically, the principle holds: maintaining physical conditioning can preserve functional capacity and quality of life even as lung function gradually declines.
Palliative care is another area that deserves earlier integration than it typically receives. Research has found that both patients and caregivers tend to equate palliative care with end-of-life care, which creates a barrier to accessing symptom management, psychological support, and advance care planning while the patient still has years of life ahead. Trials of aggressive treatment often crowd out discussions about comfort and quality of life until very late in the disease course. Transplant programs have increasingly recognized this gap, but the culture shift is slow.
Mental Health, Medication Adherence, and Survival
Depression after lung transplantation is not just a quality-of-life issue; it independently predicts worse clinical outcomes. One study found that depressed lung transplant recipients had roughly 45% higher rates of hospitalization and mortality, and that this risk was not explained by poor medication adherence alone. Depression appears to affect outcomes through multiple channels, possibly including direct effects on immune function and inflammation.
Interestingly, the relationship between anxiety and medication adherence is not what you might expect. A cross-sectional study found that recipients with anxiety symptoms were actually twice as likely to be adherent to their medications compared to non-anxious recipients, perhaps because a degree of worry motivates vigilance about pill-taking. Depression, by contrast, showed no clear link to adherence in the same study. The takeaway is that psychological wellbeing matters for survival after transplant, but the mechanisms are more complex than a simple “depressed patients skip their pills” narrative.
Outcomes in Children
Pediatric lung transplant recipients face a similar landscape. Registry data show a median survival of about 4.9 years after pediatric lung transplantation, and the incidence of bronchiolitis obliterans and key post-transplant complications tracks closely with the adult experience. Children are not spared from chronic rejection, and the developmental and psychosocial challenges of growing up with a transplanted organ and the specter of CLAD add layers of complexity that adult patients do not face. Retransplantation may be considered in pediatric patients, though the same scarcity of donor organs applies, and the decision-making is further complicated by growth considerations and lifetime immunosuppression burden.
The Lung Microbiome and Personalized Prognosis
One of the more intriguing recent developments is the recognition that the community of bacteria living in the transplanted lungs may influence both the risk of chronic rejection and the response to treatment. The study linking azithromycin’s survival benefit to high lung bacterial burden suggests that the microbiome is not just a bystander but an active player in how CLAD unfolds. Patients with different microbial profiles may have fundamentally different disease trajectories, even if their spirometry numbers look similar. This research is still in its early stages, but it points toward a future where treatment decisions are guided not just by lung function measurements and imaging but also by the biological characteristics of the individual patient’s graft. Whether microbiome-directed therapy could eventually prevent or delay chronic rejection is an open question that several research groups are actively pursuing.